Jeetvan Patel

592 total citations
25 papers, 473 citations indexed

About

Jeetvan Patel is a scholar working on Economics and Econometrics, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jeetvan Patel has authored 25 papers receiving a total of 473 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Economics and Econometrics, 9 papers in Surgery and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jeetvan Patel's work include Lipoproteins and Cardiovascular Health (9 papers), Pharmaceutical Economics and Policy (8 papers) and Health Systems, Economic Evaluations, Quality of Life (7 papers). Jeetvan Patel is often cited by papers focused on Lipoproteins and Cardiovascular Health (9 papers), Pharmaceutical Economics and Policy (8 papers) and Health Systems, Economic Evaluations, Quality of Life (7 papers). Jeetvan Patel collaborates with scholars based in United States, Netherlands and Switzerland. Jeetvan Patel's co-authors include Anand A. Dalal, Saurabh Nagar, David J. Harrison, Rolin L. Wade, Pallavi Rane, Orsolya Lunacsek, Tanya Burton, Ted Okerson, Niraj Parikh and Paul E. Schulz and has published in prestigious journals such as Journal of the American College of Cardiology, The American Journal of Cardiology and Arthritis Research & Therapy.

In The Last Decade

Jeetvan Patel

25 papers receiving 465 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jeetvan Patel United States 13 179 143 126 80 62 25 473
Sara B. Calvert United States 10 313 1.7× 99 0.7× 129 1.0× 127 1.6× 104 1.7× 20 663
Greg Cable United States 13 182 1.0× 73 0.5× 44 0.3× 53 0.7× 94 1.5× 20 561
Greta Lozano‐Ortega United States 13 86 0.5× 88 0.6× 55 0.4× 57 0.7× 93 1.5× 40 575
Syed Mohiuddin United Kingdom 14 97 0.5× 115 0.8× 108 0.9× 22 0.3× 242 3.9× 52 643
Andrew Nixon United Kingdom 14 55 0.3× 63 0.4× 164 1.3× 181 2.3× 30 0.5× 39 599
Tom Greene United States 8 180 1.0× 121 0.8× 65 0.5× 58 0.7× 85 1.4× 27 566
Allison Petrilla United States 13 80 0.4× 67 0.5× 126 1.0× 15 0.2× 141 2.3× 45 739
Koo Wilson Sweden 14 56 0.3× 74 0.5× 153 1.2× 154 1.9× 75 1.2× 44 547
Ruben G. Duijnhoven Netherlands 13 58 0.3× 78 0.5× 120 1.0× 25 0.3× 17 0.3× 36 617
Karen Murphy Ireland 11 113 0.6× 73 0.5× 53 0.4× 64 0.8× 86 1.4× 24 695

Countries citing papers authored by Jeetvan Patel

Since Specialization
Citations

This map shows the geographic impact of Jeetvan Patel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeetvan Patel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeetvan Patel more than expected).

Fields of papers citing papers by Jeetvan Patel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeetvan Patel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeetvan Patel. The network helps show where Jeetvan Patel may publish in the future.

Co-authorship network of co-authors of Jeetvan Patel

This figure shows the co-authorship network connecting the top 25 collaborators of Jeetvan Patel. A scholar is included among the top collaborators of Jeetvan Patel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeetvan Patel. Jeetvan Patel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Preusse, Peggy, et al.. (2019). Adherence to Blood Cholesterol Treatment Guidelines Among Physicians Managing Patients With Atherosclerotic Cardiovascular Disease. The American Journal of Cardiology. 124(2). 169–175. 16 indexed citations
2.
Nagar, Saurabh, Jeetvan Patel, & Richard H. Stanford. (2018). Characteristics and health care resource use of subjects with COPD in the year before initiating LAMA monotherapy or LAMA+LABA combination therapy: A U.S. database study.. PubMed. 27(5). 40–47. 2 indexed citations
3.
Baum, Seth J., Chi‐Chang Chen, Pallavi Rane, et al.. (2018). CARDIOVASCULAR RISK IN PATIENTS DENIED ACCESS TO PCSK9I THERAPY. Journal of the American College of Cardiology. 71(11). A1760–A1760. 6 indexed citations
4.
5.
Rane, Pallavi, et al.. (2018). Treatment patterns and patient characteristics among early initiators of PCSK9 inhibitors. Vascular Health and Risk Management. Volume 14. 409–418. 32 indexed citations
6.
Patel, Jeetvan, et al.. (2018). COPD affects worker productivity and health care costs. International Journal of COPD. Volume 13. 2301–2311. 40 indexed citations
7.
Stephenson, Judith J., Debra Wertz, Tao Gu, Jeetvan Patel, & Anand A. Dalal. (2017). Clinical and economic burden of dyspnea and other COPD symptoms in a managed care setting. International Journal of COPD. Volume 12. 1947–1959. 17 indexed citations
8.
Mapel, Douglas W., François Laliberté, Melissa Roberts, et al.. (2017). A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting mono- or combination therapy. International Journal of COPD. Volume 12. 1825–1836. 14 indexed citations
9.
Wilson, Michele, et al.. (2017). Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model. International Journal of COPD. Volume 12. 997–1008. 21 indexed citations
10.
Baum, Seth J., Chi‐Chang Chen, Pallavi Rane, et al.. (2017). CHARACTERISTICS OF PATIENTS APPROVED AND DENIED ACCESS TO PCSK9I THERAPY BY PAYERS. Journal of the American College of Cardiology. 69(11). 2534–2534. 4 indexed citations
11.
Rane, Pallavi, et al.. (2017). PERSISTENCE AND ADHERENCE WITH PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 INHIBITORS IN CLINICAL PRACTICE. Journal of the American College of Cardiology. 69(11). 159–159. 4 indexed citations
12.
13.
Rane, Pallavi, Jeetvan Patel, David J. Harrison, et al.. (2017). Patient Characteristics and Real-World Treatment Patterns Among Early Users of PCSK9 Inhibitors. American Journal of Cardiovascular Drugs. 18(2). 103–108. 17 indexed citations
14.
Wade, Rolin L., et al.. (2017). Estimation of Missed Statin Prescription Use in an Administrative Claims Dataset. Journal of Managed Care & Specialty Pharmacy. 23(9). 936–942. 9 indexed citations
15.
16.
Gitlin, Matthew, et al.. (2016). Cost Per Effectively Treated Patient With Evolocumab 140mg, Alirocumab 75/150mg Among Patients Using PCSK9 Inhibitor Therapy. Journal of clinical lipidology. 10(3). 685–686. 1 indexed citations
17.
Kan, Hong, Saurabh Nagar, Jeetvan Patel, et al.. (2016). Longitudinal Treatment Patterns and Associated Outcomes in Patients With Newly Diagnosed Systemic Lupus Erythematosus. Clinical Therapeutics. 38(3). 610–624. 29 indexed citations
18.
Ke, Xuehua, et al.. (2015). A Retrospective Administrative Claims Database Evaluation of the Utilization of Belimumab in US Managed Care Settings. Clinical Therapeutics. 37(12). 2852–2863. 12 indexed citations
19.
Patel, Jeetvan, Anand A. Dalal, & Saurabh Nagar. (2014). Indirect costs in chronic obstructive pulmonary disease: A review of the economic burden on employers and individuals in the United States. International Journal of COPD. 9. 289–289. 83 indexed citations
20.
Kan, Hong, Saurabh Nagar, Jeetvan Patel, Daniel J. Wallace, & C. Molta. (2014). Cluster analysis of longitudinal treatment patterns in patients newly diagnosed with systemic lupus erythematosus in the United States. Arthritis Research & Therapy. 16(Suppl 1). A52–A52. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sara B. Calvert Breakdown of academic impact, for papers by Greg Cable Breakdown of academic impact, for papers by Greta Lozano‐Ortega Breakdown of academic impact, for papers by Syed Mohiuddin Breakdown of academic impact, for papers by Andrew Nixon Breakdown of academic impact, for papers by Tom Greene Breakdown of academic impact, for papers by Allison Petrilla Breakdown of academic impact, for papers by Koo Wilson Breakdown of academic impact, for papers by Ruben G. Duijnhoven Breakdown of academic impact, for papers by Karen Murphy
Rankless by CCL
2026